Alpharma Receives FDA Approvable Status for Kadian 200-mg Capsules

Alpharma has been notified by the FDA that its pending application for Kadian 200-mg capsule has received approvable status.

Kadian is Alpharma's branded sustained-release morphine sulfate product and is currently marketed in 20-, 30-, 50-, 60- and 100-mg dosages. The company plans to launch the new dosage form following final FDA approval.